pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

1,132 catalysts · 18,987 approval · 5,000 device 510k · 4,779 phase readout · 4,728 grant · 2,387 8k filing · 2,000 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
hide past →
sort
soonestlatesttypesponsoralpha
type: filing×type: recall×clear all
type
  • approval18,987
  • device 510k5,000
  • phase readout4,779
  • grant4,728
  • 8k filing2,387
  • device pma2,000
device recall
2,000
  • recall1,126
  • device adverse event1,000
  • earnings295
  • therapy area
    • Ophthalmology5

    Week of Apr 13, 2026

    24
    ›Apr 15, 2026recall100d agoFagron Compounding Services recall (Cls II)Revalesio Corp

    Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5083-01 — Reason: Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFresenius Kabi USA, LLC recall (Cls II)Fresenius Kabi USA LLC

    0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 100 mL in a Single Dose freeflex bag, Rx only, BD Beckton, Dickson and Company, 1 Beckton Drive, Franklin Lakes, NJ 07417 USA, Distributed by BD, Manufactured by: Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Sale NDC Number: 17271-701-03. — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoGE Healthcare Ireland Limited recall (Cls II)Amneal Pharmaceuticals, Inc.

    GE Healthcare Omnipaque (iohexol) Injection, 350 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1414-91. — Reason: Presence of particulate matter — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoCipla USA, Inc. recall (Cls II)Cipla USA Inc

    Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only, Rx Only, Manufactured by: Pharmathen International, S.A., Rodopi, Greece. Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC 69097-906-67 — Reason: Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure. — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFresenius Kabi USA, LLC recall (Cls II)Fresenius Kabi USA LLC

    5% Dextrose Injection, USP 2.5 g per 50 mL (50 mg per mL) 50 mL in a 100 mL freeflex bag, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Use NDC: 65219-456-05, Unit of Sale NDC Number: 65219-456-60. — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoTeva Pharmaceuticals USA, Inc recall (Cls II)Terns Pharmaceuticals, Inc.

    Clonidine Transdermal System, USP, 0.3 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx only, Manufactured by: Actavis Laboratories UT Inc., Salt Lake City, UT 84108, Distributed by: Actavis Pharma, Inc, Parsippany, NJ, NDC 0591-3510-04 carton, NDC 0591-3510-54 pouch — Reason: CGMP Deviations: use of an unapproved raw material — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFagron Compounding Services recall (Cls II)Baxter Healthcare Corp

    norepinephrine Bitartrate, 32mg per 250mL 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5027-02 — Reason: Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFresenius Kabi USA, LLC recall (Cls II)Fresenius Kabi USA LLC

    5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 mL freeflex bag, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Use NDC: 65219-458-05, Unit of Sale NDC Number: 65219-458-30. — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFresenius Kabi USA, LLC recall (Cls II)Fresenius Kabi USA LLC

    5% Dextrose Injection, USP 5 g per 100 mL (50 mg per mL) 100 mL in a 100 mL freeflex bag, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Use NDC: 65219-464-05, Unit of Sale NDC Number: 65219-464-50. — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFresenius Kabi USA, LLC recall (Cls II)Fresenius Kabi USA LLC

    0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 1,000 mL in a Single Dose freeflex bag, 1,000 mLx10, Fresenius Medical Care, Waltham, MA 02451, Distributed by: Fresenius Medical Care RTG, LLC, Manufactured by: Fresenius Kabi, Unit of Use NDC: 65219-282-01, Unit of Sale NDC Number: 65219-282-10. — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoViatris, Inc. recall (Cls II)Viatris Inc

    Xanax XR, alprazolam, extended-release tablets, 3 mg, 60 Tablets bottles, Rx only, Distributed by: Viatris Specialty LLC, Morgantown, WV 06506, U.S.A, Made in Ireland, NDC 58151-506-91 — Reason: Failed Dissolution Specifications — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoPreferred Pharmaceuticals, Inc. recall (Cls II)InMed Pharmaceuticals Inc.

    Artificial Tears Lubricant Eye Drops (glycerin 0.2%, hypromellose 0.2%, polyethylene glycol 400 1%), 0.5 oz bottles, Mfg: Geri-Care; Brooklyn, New York NDC 68788-7266-0 — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFagron Compounding Services recall (Cls II)Baxter Healthcare Corp

    norepinephrine Bitartrate,16mg per 250mL 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5026-02 — Reason: Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFresenius Kabi USA, LLC recall (Cls II)Fresenius Kabi USA LLC

    0.9% Sodium Chloride Injection, USP 0.9% (450 mg per 50 mL) (9 mg per mL) 50 mL, Rx only, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Lake Zurich, IL 60047, Unit of Use NDC: 65219-466-05, Unit of Sale NDC Number: 65219-466-60. — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFresenius Kabi USA, LLC recall (Cls II)Fresenius Kabi USA LLC

    0.9% Sodium Chloride Injection, USP, 50 mL x60, Becton, Dickson and Company, 1 Beckton Drive, Franklin Lakes, NJ 07417 USA, Distributed by BD, Manufactured by Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Sale NDC Number: 17271-701-02. — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFresenius Kabi USA, LLC recall (Cls II)Fresenius Kabi USA LLC

    0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 250 mL in a Single Dose freeflex bag, Rx only, BD Becton, Dickson and Company, 1 Beckton Drive, Franklin Lakes, NJ 07417, Distributed by BD, Manufactured by: Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Sale NDC Number: 17271-701-05. — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoTeva Pharmaceuticals USA, Inc recall (Cls II)Terns Pharmaceuticals, Inc.

    Isotretinoin Capsules, USP, 40 mg, 10 count Prescription Pacs, Rx only, Manufactured for: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 0591-2436-15 (carton), NDC 0591-2436-45 (blister pack). — Reason: Superpotent and Subpotent — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFagron Compounding Services recall (Cls II)Revalesio Corp

    Vancomycin HCL, 1 gram added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5082-01 — Reason: Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoGE Healthcare Ireland Limited recall (Cls II)Amneal Pharmaceuticals, Inc.

    GE Healthcare Omnipaque (iohexol) Injection, 300 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1413-63. — Reason: Presence of particulate matter — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoTeva Pharmaceuticals USA, Inc recall (Cls II)Terns Pharmaceuticals, Inc.

    Isotretinoin Capsules, USP, 30 mg, Rx Only, 10 count Prescription Pack, Manufactured for: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 0591-2435-15 (carton), NDC 0591-2435-45 (blister pack). — Reason: Superpotent and Subpotent — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoFresenius Kabi USA, LLC recall (Cls II)Fresenius Kabi USA LLC

    0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL), 1,000 mL in a Single Dose freeflex bag, Rx only, BD Becton, Dickson and Company, 1 Becton Drive, Franklin Lakes, NJ 07417, Distributed by BD, Manufactured by Fresenius Kabi, Unit of Sale NDC Number: 17271-701-07. — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 15, 2026recall100d agoCipla USA, Inc. recall (Cls II)Cipla USA Inc

    Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1 safety needle, Single dose only, Rx Only, Manufactured by: Pharmathen International, S.A., Rodopi, Greece. Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67 — Reason: Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure. — Status: Ongoing

    full page →fda recalls ↗
    ›04/16/2026recall99d agoLoard’s recall: Food & Beverages, Allergens, Ice Cream/Frozen Dairy

    Ice Cream

    full page →fda recalls ↗
    ›04/17/2026recall98d agoBreeder’s Edge, Shelter’s Choice recall: Animal & Veterinary, Food & Beverages

    Canine milk replacer

    full page →fda recalls ↗

    Week of Apr 20, 2026

    2
    ›04/20/2026recall95d agoAligned Medical Angio Pack recall: Medical Devices

    Angio Packs (AMS6908E and AMS6908F)

    full page →fda recalls ↗
    ›04/23/2026recall

    Week of Apr 27, 2026

    6
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing
    ← prev
    page 23 of 23
    next →
    92d ago
    Frederik’s by Meijer recall: Food & Beverages, Allergens

    Vanilla Bourbon Trail Mix

    full page →fda recalls ↗
    85d ago
    Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Choroidal Neovascularization

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoSarepta Therapeutics Inc — golodirsen (NDA/BLA Filing (US))golodirsen

    Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy

    full page →golodirsen →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing85d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

    full page →ranibizumab biosimilar →source: globaldata
    $AMRX17.97+1.24%
    $TERN52.95-0.03%
    $TERN52.95-0.03%
    $VTRS17.28+1.59%
    $TERN52.95-0.03%
    $AMRX17.97+1.24%
    $INM1.8500+11.45%
    $SRPT15.88+0.38%